Effect of different dopaminergic agents in the treatment of acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 2, 1997, Pages 518-523

  Colao, Annamaria ^a   Ferone, Diego ^a   Marzullo, Paolo ^a   Di Sarno, Antonella ^a   Cerbone, Gaetana ^a   Sarnacchiaro, Francesca ^a   Cirillo, Sossio ^a   Merola, Bartolomeo ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GROWTH HORMONE; PROLACTIN; QUINAGOLIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYPOTENSION; LONG TERM CARE; MALE; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

EID: 0031026529     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.2.3648     Document Type: Article

References (18)

1. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 13:220-240.
2. Oppizzi G, Liuzzi A, Chiodini PG, et al. 1984 Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J Clin Endocrinol Metab. 58:988-992.
3. Bell PM, Atkinson AB, Hadden DR, et al. 1986 Bromocriptine reduces growth hormone in acromegaly. Arch Intern Med. 146:1145-1149.
4. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Recent advances in pathology, diagnosis and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
5. Quabbe HJ. 1981 Treatment results in 235 patients with acromegaly. A report of the acromegaly study group. Acta Endocrinol (Copenh). [Suppl]240:66.
6. Lamberts SWJ, van Der Lely AJ, de Herder WW, Hofland J. 1996 Octreotide. N Engl J Med. 334:246-254.
7. Chiodini PG, Attanasio R, Cozzi R, et al. 1993 CV 205-502 in acromegaly. Acta Endocrinol (Copenh). 128:389-393.
8. Lombardi G, Colao A, Ferone D, et al. 1995 CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol. 132:559-564.
9. Ferrari C, Paracchi A, Romano C, et al. 1988 Long-lasting lowering of serum growth hormone and prolactin levels by single or repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf). 29:467-476.
10. Grossman A, Ross R, Wass JAH, Besser GM. 1986 Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin Endocrinol (Oxf). 24:231-238.
11. Plockinger U, Quabbe HJ. 1991 Evaluation of a repeatable depot-bromocriptine preparation (Parlodel L AR®) for the treatment of acromegaly. J Endocrinol Invest. 14:943-948.
12. Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N. 1995 Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas. Clin Endocrinol (Oxf). 42:593-599.
13. Schettini G, Lombardi G, Merola B, et al. 1990 Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol (Oxf). 33:161-169.
14. Melmed S, Dowling H, Frohman L, et al. 1994 Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med. 97:468-473.
15. Karashima T, Kato K, Nawata H, et al. 1986 Long term bromocriptine therapy and predictive tests in acromegaly. Endocrinol Jpn. 33:163-167.
16. Nortier JWR, Croughs RJM, Donker GH, et al. 1984 Change in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests. Acta Endocrinol (Copenh). 106:175-183.
17. Lamberts SWJ, Zweens M, Verschoor L, del Pozo E. 1986 A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J Clin Endocrinol Metab. 63:16-19.
18. Fløgstad AK, Halse J, Grass P, et al. 1994 A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab. 79:461-465.